Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Chemotherapy in HPV16+ Oropharyngeal Cancer
NCT07290621Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in oropharyngeal cancer, sponsored by University of Chicago. Primary endpoint: Deep Response Rate at 3 months. Started Feb 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT07290621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290621.